A plain-language guide

autoimmune hepatitis

What's known, what's still uncertain, and what's actively debated, written plainly, and built only from published medical research.

Early map · 7 sourced statements Every statement names its source Updated 2026-08-04
Please read this first. This guide is a companion to your medical team, not a replacement, and it is not medical advice. Everything here is tied to published research. If something you expected is not here, it almost always means we have not mapped a source for it yet, not that it is unknown to medicine. autoimmune hepatitis is an early, growing map, so it will look incomplete on purpose: we would rather show less and have every line be something you can check than fill the page with claims we cannot stand behind. For anything about your own situation, your clinicians hold the full picture. How this guide is built and why.

What's autoimmune hepatitis?

Autoimmune hepatitis is a chronic inflammatory liver disease in which the immune system attacks the liver, marked by high immunoglobulin levels and circulating autoantibodies, and more common in women.

Features mapped5
Treatments mapped1
Published sources4
Last reviewed2026-08-04

Signs and symptoms

Elevated circulating hepatic transaminase concentration

Raised liver enzymes (transaminases) in the blood are a typical sign of active autoimmune hepatitis.

Limited evidenceSource: PMID:42377010
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:42298428, ORPHA:2137
Notesplain_language confirmed from PMID:42298428 via curation 2026-07-03 [llm:fable-5]. | regrounded primary ORPHA:2137 -> PMID:42377010 on 2026-07-03 [Carrie Schluter, BCPA]
Last reviewed2026-07-03

Antinuclear antibody positivity

Many people with autoimmune hepatitis have antinuclear antibodies (ANA), a self-directed antibody, detectable in the blood.

Limited evidenceCurated reference: ORPHA:2137
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:42160115
Notesplain_language confirmed from PMID:42160115 via curation 2026-07-03 [llm:fable-5].
Last reviewed2026-07-03

Cirrhosis

Over time, autoimmune hepatitis can progress to cirrhosis, scarring of the liver.

Limited evidenceSource: PMID:42229718
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:42217578, ORPHA:2137
Notesplain_language confirmed from PMID:42217578 via curation 2026-07-03 [llm:fable-5]. | regrounded primary ORPHA:2137 -> PMID:42229718 on 2026-07-03 [Carrie Schluter, BCPA]
Last reviewed2026-07-03

Jaundice

Jaundice, a yellowing of the skin and eyes, can occur in autoimmune hepatitis.

Limited evidenceCurated reference: ORPHA:2137
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:42298428
Notesplain_language confirmed from PMID:42298428 via curation 2026-07-03 [llm:fable-5].
Last reviewed2026-07-03

Increased circulating IgG concentration

Blood levels of immunoglobulin G (IgG) antibodies are typically raised in autoimmune hepatitis.

Limited evidenceSource: PMID:42229718
Evidence ratingweak
Study designontology_import
Confidence (0-1)0.7
Replicationunreplicated
Supporting sourcesPMID:42252183, ORPHA:2137
Notesplain_language confirmed from PMID:42252183 via curation 2026-07-03 [llm:fable-5]. | regrounded primary ORPHA:2137 -> PMID:42229718 on 2026-07-03 [Carrie Schluter, BCPA]
Last reviewed2026-07-03

Treatment and management

What the research describes, not a recommendation. Treatment decisions belong with your clinician.

This covers treatments that appear in the published research mapped here. Investigational and experimental therapies are not included, so their absence is a boundary of this map, not a sign they do not exist.

corticosteroids

Corticosteroids such as prednisone are the mainstay treatment for autoimmune hepatitis and reduce raised transaminases and liver inflammation.

Used to help with: Elevated circulating hepatic transaminase concentration.

Limited evidenceSource: PMID:42163288
The source text this rests on
“Both ADSC and prednisone monotherapies significantly reduced serum transaminases (ALT, AST, ALP, TBIL) and hepatic inflammation compared with untreated controls.”
An excerpt quoted verbatim from the source named above, shown as recorded. The full sentence is in the linked source.
Evidence ratingweak
Confidence (0-1)0.7
Replicationunreplicated
Notesconfirmed from PMID:42163288 via curation 2026-07-03
Last reviewed2026-07-03

How to read the evidence labels

Widely acceptedSpecialists broadly agree on this.
Strong evidenceBacked by solid, repeated research.
Moderate evidenceReasonable evidence, still being confirmed.
Limited evidenceSome evidence, but not yet convincing.
Early evidenceAn early finding that needs more study.
Experts disagreeResearchers actively disagree about this.
No longer supportedLater, stronger evidence or guidance overturned this.

Where this comes from

This guide is built from 4 published source(s). Every claim above links back to one of them. Click any source ID to read the original on PubMed.

ORPHA:2137 · Orphanet/HPO annotations for Autoimmune hepatitis
PMID:42163288 · Adipose tissue-derived mesenchymal stem cells combined with prednisone synergistically ameliorate autoimmune hepatitis i
PMID:42229718 · Risk factors for poor response to autoimmune hepatitis: A systematic review and meta-analysis.
PMID:42377010 · Fibrosis-4 and Aspartate Aminotransferase-to-Platelet Ratio Index as Predictors of Relapse in Autoimmune Hepatitis: A Retrospective Single-Center Study.

Take it further

Printed, source-linked documents built from this condition's graph — ready to bring to an appointment or attach to a coverage request. Every claim carries its published source, the same as this guide.